2024-10-19 - Analysis Report
## Regeneron Pharmaceuticals Inc. (REGN) Stock Analysis:

**1. Performance Comparison:**

* **Company Overview:** Regeneron Pharmaceuticals Inc. is a leading biotechnology company focused on developing and commercializing life-transforming medicines for serious diseases. 
* **Cumulative Return:** 90.34% (REGN) vs. 136.97% (VOO)
* **Return Difference:** -46.63% 
* **Relative Divergence:** 30.2% (meaning REGN is currently performing at the 30.2 percentile of its historical performance relative to VOO)

**2. Recent Price Movements:**

* **Closing Price:** $998.23
* **5-day Moving Average:** $1010.53
* **20-day Moving Average:** $1031.56
* **60-day Moving Average:** $1105.20

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 25.69 (suggests oversold conditions)
* **PPO (Percentage Price Oscillator):** 0.06 (suggests potential for price momentum)
* **Delta_Previous_Relative_Divergence:** -27.15 (indicates a short-term downtrend)
* **Expected Return:** 0.0% (expected return over 5 years, relative to VOO)

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | $3.55 B | 
| 2024-05-02 | 6.7 | $3.15 B |
| 2023-11-02 | 9.48 | $3.36 B |
| 2023-08-03 | 9.05 | $3.16 B |
| 2024-08-01 | 9.05 | $3.16 B |

The most recent earnings report for Q2 2024 (released on August 01, 2024) exceeded analysts' estimates for both earnings per share (EPS) and revenue. 

**5. News & Recent Issues:**

* **Recent Market Outlook:** While REGN has underperformed the market in recent times, analysts remain optimistic about its long-term prospects due to its strong pipeline of innovative drugs and its focus on high-growth areas such as ophthalmology and oncology.
* **Analyst Opinions & Performance Highlights:**  
    * **Finbold:**  Analysts have mixed views on REGN. Some highlight the strong pipeline and the company's dominance in certain therapeutic areas while others caution about potential competition and the impact of the current economic environment.
    * **Other Sources:** You can further explore analyst opinions on platforms like Seeking Alpha, Yahoo Finance, and Bloomberg. 

**6. Overall Analysis:**

REGN has underperformed the broader market (VOO) in the recent past.  However, its recent earnings beat, its strong pipeline, and the potential for growth in its therapeutic areas suggest it could outperform in the future. The stock currently appears to be oversold, and its technical indicators suggest a potential for price momentum.  

**7. Key Takeaways:**

* REGN has underperformed the market in the recent past but has strong long-term potential.
* The stock is currently oversold, presenting a potential buying opportunity.
* The company's strong pipeline and focus on high-growth therapeutic areas are key growth drivers. 
* It's important to monitor the company's future earnings reports, news, and analyst opinions for further insights. 

**Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. Please consult a financial professional before making any investment decisions. 
